Protalix BioTherapeutics Logo
US74365A3095
A2PWSL
PLX

Protalix BioTherapeutics

Forecast

The analysts' average price target is €5.47 (+107.98%). The median is €5.47 (+107.98%).

Buy
  5
Hold
  2
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket

    Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » More on de.investing.com


  • Protalix beats revenue expectations but misses EPS and shares plunge

    Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » More on de.investing.com


  • Protalix partners with Secarna to develop antisense therapies for rare kidney diseases

    Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » More on de.investing.com


  • Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket

    Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » More on de.investing.com


  • Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio

    Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » More on de.investing.com

Financials

In the last quarter, Protalix BioTherapeutics had revenue of €19.36M and net profit of €3.5M

(EUR) September 2026
YoY
Revenue 19.36M 27.25%
Gross profit 12.4M 52.78%
Net profit 3.5M 74.26%
EBITDA 4.47M 88.09%

Fundamentals

Metric Value
Market capitalization
€232.07M
Number of shares
84.32M
52-week high/low
€2.91 - €1.50
Dividends No
Beta
0.01
P/E ratio
11.61
PEG ratio
-0.02
P/B ratio
3.02
P/S ratio
3.01

Company profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Name
Protalix BioTherapeutics
CEO
Dror Bashan
Headquarters Hackensack, nj
Israel
Website
Sector
Consumer Staples
Industry
Food Products
IPO
05/15/1998
Employees 226

Ticker symbols

Exchange Symbol
AMEX
PLX
Frankfurt
PBDA.F
DĂĽsseldorf
PBDA.DU
MĂĽnchen
PBDA.MU
🍪

Parqet  uses cookies. Learn more